Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis

Exclusion Criteria

• •Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
• •Vascular access insufficiency (mean blood flow \<200ml/min)
• •Patients treated with dialysis profiles: sodium profile, Ultrafiltration (UF) profile, and temperature profile - changed to: " Patients treated with dialysis profiles during the 9 prescreening visits: sodium profile, UF profile, and temperature profile. However, patients on sodium, ultrafiltration or temperature profiling expected to reduce intradialytic hypotensive episodes can be evaluated for enrollment when their frequency of sessions complicated by hypotension demonstrate the lack of efficacy of the applied profiles" with Amendment 1 (CIP version 6)
• •Use of the BioLogic fusion function during the last 9 dialysis sessions recorded at the site (retrospective screening period)
• •Pregnant or nursing women. Women of childbearing potential must agree to avoid pregnancy during the study period
• •Factors which may interfere with full participation in the trial
• •Any contra-indication to haemodialysis treatment per se, as described in the Instructions for Use (IFU)
• •Any serious medical condition or disability, which in the opinion of the investigator limits the life expectancy and would preclude completion of the study